Compass Completed the First Psilocybin NDA. Three Things Still Have to Happen, and None Has a Date
Compass Pathways completed its New Drug Application for COMP360 psilocybin on November 9. The indication is treatment-resistant depression. It is the first completed psilocybin NDA in the United States.
The company says launch readiness is on track for the first half of 2027. Three things have to happen first, and the release puts a date on none of them.
Whatever arrives in 2027, the cost base you run today is negotiable. HealingMaps’ GPO, the first built for the ketamine industry, gets member clinics 15 to 20 percent off malpractice and liability premiums, 40 percent or more off medical supplies, discounted LegitScript certification, and 20 to 30 percent off HIPAA compliant payment processing. Joining is free with no obligation. See what your clinic qualifies for →
| Key Takeaway | Detail |
|---|---|
| What happened | Compass completed its NDA submission for COMP360 psilocybin on November 9, 2026 |
| Indication | Treatment-resistant depression, defined as inadequate response to two or more antidepressants |
| The evidence | Two Phase 3 trials and a Phase 2b, each met its primary endpoint, 1,000+ participants |
| Designations | Breakthrough Therapy in the US, ILAP in the UK, and a National Priority Voucher |
| What is missing | No FDA filing acceptance, no review decision date, no published PDUFA date |
| The other gate | Psilocybin is Schedule I. Compass says it must be rescheduled before US commercialization |
| Company guidance | Launch expected in the first half of 2027, subject to FDA approval |
What was actually filed
Compass announced the completed submission on November 9. The application covers COMP360 psilocybin for treatment-resistant depression. The company defines that as an inadequate response to two or more courses of antidepressants at adequate dose and duration.
The filing rests on two Phase 3 trials and a Phase 2b study. Compass says each met its primary endpoint, across more than 1,000 participants with highly chronic treatment-resistant depression.
The release does not name the individual studies, give per-trial participant counts, or state effect sizes. Those will matter when the data is published, and they are not in this announcement.
COMP360 holds Breakthrough Therapy designation in the United States and ILAP designation in the United Kingdom. The company also references a National Priority Voucher and the grant of rolling review.
Three gates, no dates
An NDA submission is not an approval, and it is not even an acceptance. FDA has to decide whether to file the application before the review clock starts.
The release reports no filing acceptance, no review decision date and no PDUFA date. The chief executive says the company looks forward to continuing the review process, which is as specific as it gets.
The second gate is scheduling. Psilocybin is a Schedule I controlled substance. Compass states in its own risk language that it must be rescheduled before COMP360 can be commercialized in the United States.
The company goes further. It warns that the DEA and the states may not reschedule the product on a timely basis, or at all. That is the sponsor describing its own downside.
The third gate is the risk evaluation and mitigation strategy. The release does not mention one. It does not describe a dosing setting, or say who would administer the drug.
Why the REMS silence matters most to you
For a clinic, the REMS is the document that decides whether this is a business. It sets the setting, the monitoring, the certification and the supply chain.
Spravato is the precedent. Its REMS restricts administration to certified healthcare settings, requires a prescriber on site, and mandates a monitoring period after dosing. That is what turned esketamine into a clinic-shaped product.
Nothing comparable has been published for COMP360. We looked at who actually hands approved psilocybin to a patient. The answer still depends on a document nobody outside the process has seen.
Compass has said Spravato clinics are the closest model for its own rollout. We checked that against our directory data on how much the two footprints overlap.
The timeline has slipped before
The vouchers were issued in April. At the time, the FDA commissioner suggested the first psychedelic approval could arrive by the end of summer 2026.
It is November and nothing has been approved. That same voucher is now cited as the reason a decision could move quickly. It is a claim about process, not a date.
We tracked this race in our look at why the two front-runners are not chasing the same patients. Usona is pursuing major depressive disorder, the broader diagnosis.
Treat every date in this category as an estimate from an interested party. That includes the ones here.
What is worth doing now
Not much, and that is the point. There is no product, no REMS and no approval date.
What is worth doing is deciding whether you want to be in the first cohort if it arrives. The clinics best placed are the ones already running a monitored, certified service with a documented outcome record.
That is the same list as last year, which is the useful part. The preparation for an approval you cannot schedule is indistinguishable from running a good clinic now.
Patients comparing supervised options can start with our directory of verified ketamine clinics.
This article is for informational purposes and is not medical or investment advice. COMP360 is investigational and has not been approved by the FDA. All figures are as reported by Compass Pathways.
